Logo

Coherus’s Receives the US FDA’s Approval of CHS-1420 (biosimilar, adalimumab) for the Treatment of Chronic Plaque Psoriasis

Share this

Coherus’s Receives the US FDA’s Approval of CHS-1420 (biosimilar, adalimumab) for the Treatment of Chronic Plaque Psoriasis

Shots:

  • The approval is based on a (CHS-1420-02) study to evaluate the efficacy, safety & immunogenicity of Yusimry vs Humira in 545 subjects with moderate to severe chronic PsO
  • The results showed that Yusimry was equivalent to adalimumab based on the 1EPs, 75% improvement in PASI-75 @12wks. Additionally, the CHS-1420-03 trial assessed the PK bioequivalence of Yusimry vs Humira after SC administration of a single (40mg) dose & demonstrated similarity on all PK endpoints
  • Yusimry is Coherus' second FDA-approved product & is expected to launch in the US on July 2023, under the collaboration with AbbVie

Ref: Globe Newswire | Image: Coherus

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions